VTVT - vTv Therapeutics Inc

VTVT - vTv Therapeutics Inc

https://vtvtherapeutics.com

Recent News

Powered by Alpha Vantage

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire • 1 week, 4 days ago • score: 0.44

HIGH POINT, N.C., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- vTv Therapeutics Inc. ( Nasdaq: VTVT ) , a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 ...

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin - vTv Therapeutics ( NASDAQ:VTVT )

Benzinga • 1 month ago • score: 0.50

HIGH POINT, N.C., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- vTv Therapeutics Inc.

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

GlobeNewswire • 1 month ago • score: 0.51

HIGH POINT, N.C., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- vTv Therapeutics Inc. ( Nasdaq: VTVT ) , a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ...

This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Mastercard ( NYSE:MA ) , Couchbase ( NASDAQ:BASE )

Benzinga • 5 months ago • score: 0.14

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Chardan Capital analyst Geulah Livshits initiated coverage on Palvella Therapeutics, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops and sells candidates for orally administered small molecule drugs to meet unmet medical needs.

52W High

$26.99

52W Low

$12.62

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.64

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.11

EV/Revenue (<3 favorable)

1298.72

P/S (TTM) (<3 favorable)

2818.90

P/B (<3 favorable)

17.35

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

35.51%

Institutions (25–75% balanced)

22.63%

Shares Outstanding

2,617,200

Float

644,570

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

17,000

Gross Profit (TTM)

-11,780,000

EPS (TTM)

-2.92

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-1507.18%

ROE (TTM) (>15% strong)

-2.09%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—